Brief: Alphamab Oncology Says Phase III Study Of KN026 With HB1801 Met Primary Endpoint
31/03/2026 14:38
March 31 (Reuters) - Alphamab Oncology 9966.HK: PHASE III STUDY OF KN026 WITH HB1801 FOR HER2+ BC MET PRIMARY ENDPOINT Further company coverage: 9966.HK ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Alphamab Oncology
See all newsAlphamab climbs most in over 8 weeks on progress of breast cancer treatment
Brief: Alphamab Oncology Says Phase III Clinical Study Of Anbenitamab Met Primary Endpoint
Brief: Alphamab Oncology Says CEO Buys 554,000 Shares On June 4
Brief: Alphamab Oncology Says Phase III KN026-004 Study Enrolls 521 Patients And Meets Primary Endpoint
Brief: Alphamab Oncology Says Phase III Study Of KN026 With HB1801 Met Primary Endpoint